SynthesisInternational journal of molecular sciences2026
MicroRNAs and Cellular Senescence in Melanoma: An Underexplored Link to Tumor Progression-A Systematic Review with Bioinformatics Analyses.
Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
MicroRNAs are important regulators of melanoma progression; however, their relationship with cellular senescence remains poorly understood. To address this gap, a systematic review was conducted following PRISMA 2020 guidelines and prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) under registration number CRD420251155760. A comprehensive search of PubMed, Scopus, Embase, and Dimensions identified studies evaluating melanoma-associated microRNAs and their effects on cell cycle regulation. Risk of bias was assessed using the SYRCLE tool and an adapted version of ToxRTool, with the included studies classified as having low, moderate, or high risk of bias. Fifteen studies met the eligibility criteria. Most studies reported that microRNA modulation reduced melanoma proliferation through cell cycle arrest; however, only two directly assessed senescence-associated markers. Of the fifteen identified microRNAs, seven had predicted targets and were included in the bioinformatic analysis. Integration of these predictions with genes downregulated in high-risk melanoma and underexpressed during cellular senescence identified 158 shared genes. Subsequent analysis identified predicted targets within this gene set only for hsa-miR-195-5p, and hsa-miR-425-5p, highlighting
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.